Prime Medicine reverses course to seek FDA approval of shelved therapynews2026-03-03T20:48:13+00:00March 3rd, 2026|Endpoints News|
Kyowa Kirin ends OX40 trials after Amgen balked, safety concernnews2026-03-03T20:04:15+00:00March 3rd, 2026|Endpoints News|
Theravance ends R&D, lays off 50% of workers after Phase 3 failnews2026-03-03T15:00:39+00:00March 3rd, 2026|Endpoints News|
Boehringer Ingelheim tried to use a tempting, tough cancer target for liver disease. It didn’t worknews2026-03-03T14:32:05+00:00March 3rd, 2026|Endpoints News|
United Therapeutics to take pulmonary hypertension drug to FDA for approvalnews2026-03-02T16:24:51+00:00March 2nd, 2026|Endpoints News|
Roche gets third pivotal win with MS drug, but liver signal could be a problemnews2026-03-02T15:25:33+00:00March 2nd, 2026|Endpoints News|
FDA lifts hold on second Intellia Phase 3 gene editing trialnews2026-03-02T15:23:14+00:00March 2nd, 2026|Endpoints News|
UniQure says FDA prefers randomized trial for Huntington’s treatmentnews2026-03-02T12:35:27+00:00March 2nd, 2026|Endpoints News|
Novartis’ Rhapsido shows promise in Phase 2 food allergy datanews2026-02-28T19:45:09+00:00February 28th, 2026|Endpoints News|
Merck looks to expand Welireg label following combo readouts with Keytruda, Lenvimanews2026-02-28T15:00:54+00:00February 28th, 2026|Endpoints News|
